Location United Kingdom, Europe Regions Europe, Middle East, and Africa (EMEA) Gender Male
Dr Chaplin is Chief Scientific Officer (CSO) of Mateon, bringing more than 30 years of experience in oncology research and drug development.
In addition to Dr Chaplin’s current role as CSO and Head of Research and Development at Mateon, he has also served as President and Chief Executive Officer. He has been a leader in the field of vascular
targeting and was the first to discover the vascular disrupting action of CA4P (combretastatin A4-phosphate or fosbretabulin). His original work formed the basis for not only the development of CA4P with Mateon, but also the vascular targeting development programs at AstraZeneca and Aventis. Prior to his association with Mateon, Dr Chaplin was Vice President, Oncology at Aventis Pharma in Paris. Before the merger of Rhone Poulenc Rorer (RPR) with Hoechst Marion Roussell, Dr Chaplin was Senior Director of Oncology at RPR from 1998 to 1999. From 1992 to 1998, Dr Chaplin led the Cancer Research Campaign’s (CRC) Tumor Microcirculation Group, based at the Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, London. Dr Chaplin also served as Section Head of Cancer Biology at Xenova in the United Kingdom and held a senior staff appointment at the British Columbia Cancer Research Centre.
Educated in the United Kingdom, Dr Chaplin has a BSc in chemistry from the University of Essex, a MSc in pharmacology from the University of Southampton, and a PhD in tumor biology from the University of London.
